Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Recruiting × Ovarian Cancer Recurrent × Clear all

Phase

Phase EARLY_PHASE1 1 Phase 2/3 1 Phase 2 1 Phase 1/2 1

Status

Unknown 2 Recruiting 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 150 Neoplasms 113 Colorectal Neoplasms 95 Breast Neoplasms 89 Pancreatic Neoplasms 80 Leukemia, Myeloid, Acute 78 Recurrence 77 Neoplasm Metastasis 76 Melanoma 73 Ovarian Neoplasms 71 Prostatic Neoplasms 69 Multiple Myeloma 68 Stomach Neoplasms 59 Squamous Cell Carcinoma of Head and Neck 55 Lung Neoplasms 55 Triple Negative Breast Neoplasms 50 Glioblastoma 49 Lymphoma 48 Advanced Solid Tumor 44 Endometrial Neoplasms 43 Carcinoma, Hepatocellular 43 Precursor Cell Lymphoblastic Leukemia-Lymphoma 42 Lymphoma, Non-Hodgkin 40 Uterine Cervical Neoplasms 35 Small Cell Lung Carcinoma 34 Carcinoma, Renal Cell 33 Advanced Solid Tumors 32 Lymphoma, Large B-Cell, Diffuse 31 Sarcoma 30 Lymphoma, B-Cell 30

Interventions

pembrolizumab 1 Paclitaxel 1 Carboplatin 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06843447 2026-03-27

MK-5909-003

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon ⚡